Monographie - Vincristine sulfate

آخر تحديث :
19/11/2024

Vincristine sulfate

التركيب الكيميائي

حجز الاسم التجاري

تحذير الأسماء التجاريه المختلفه قد تحتوي علي محتوي إضافات مختلفة حسب الدوله و المعمل

Cellecristin	ألمانيا
Citomid	المكسيك, بيرو, تشيلي, كولومبيا
Crisovin	الإكوادور, المكسيك, كولومبيا
Cytocristin	ماليزيا
DBL vincristine sulfate	زيلاندا الجديدة, ماليزيا
Farmistin	ألمانيا
Marqibo	الولايات المتحدة
Nefixol	المكسيك
Oncocristin	كولومبيا
Oncovin	الإمارات العربية المتحدة, الدنمارك, السويد, العربية السعودية, المغرب, المكسيك, النمسا, بريطانيا العظمي, سويسرا, فرنسا, فنلندا, كولومبيا, لوكسمبورغ
Onkocristin	ألمانيا
Sindovin	إيران
Sulfato de vincristine	فنزويلا
Unicristin	بيرو
Vinblax	المكسيك
Vincasar	المكسيك, الولايات المتحدة
Vincrisin	بلجيكا
Vincristin	ألمانيا, النمسا, سويسرا, هنغاريا
Vincristina	أيسلندا, إسبانيا, إيران, إيطاليا, الأرجنتين, الإكوادور, بيرو, تشيلي, فنزويلا, كولومبيا
Vincristine	السويد, المغرب, النرويج, تركيا, تونس, سويسرا, فرنسا, لوكسمبورغ, ماليزيا, يونان
Vincristine sulfat	تركيا
Vincristine sulfate	الولايات المتحدة, كندا
Vincristine sulphate	الإمارات العربية المتحدة, ايرلندا, بريطانيا العظمي, بولندا, زيلاندا الجديدة, ماليزيا, مصر
Vincristinesulfaat	هولندا
Vincristinum	لوكسمبورغ
Vincrisul	إسبانيا
Vinlon Lyo	بيرو
Vinracine	ماليزيا, مصر
Vintec	المكسيك

مراجع : Vincristine sulfate

	نوع	منشور
3	مجلة	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26	مجلة	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
32	مجلة	Nyhammar EK, Johansson SG, Seiving BE. Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs. Am J Health-Syst Pharm 1996 ; 53: 1171-1173.
57	مجلة	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	مجلة	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	مجلة	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	مجلة	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144	مجلة	Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm 1991 ; 77: 279-285.
150	مجلة	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
167	مجلة	Francomb MM, Ford JL, Lee MG. Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters. Int J Pharm 1994 ; 103: 87-92.
169	مجلة	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	مجلة	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	مجلة	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	مجلة	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	مجلة	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	مجلة	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	مجلة	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	مجلة	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
408	مجلة	Beijnen JH, Neef C, Meuwissen OJAT, Rutten JJMH, Rosing H, Underberg WJM. Stability of intravenous admixtures of doxorubicin and vincristine. Am J Hosp Pharm 1986 ; 43: 3022-3027.
431	مجلة	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
481	مجلة	Beijnen JH, Vendrig DEMM, Underberg WJM. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol 1989 ; 43: 84-87.
491	مجلة	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	مجلة	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
703	مجلة	Butler LD, Munson JM, DeLuca PP. Effect of inline filtration on the potency of low-dose drugs. Am J Hosp Pharm 1980 ; 37: 935-941.
763	مجلة	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
857	مجلة	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	مجلة	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	مجلة	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	مجلة	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033	مجلة	Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999 ; 56: 985-989.
1408	مجلة	Priston MJ, Sewell GJ. Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump. J Oncol Pharm Practice 1998 ; 4: 143-149.
1410	مجلة	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	مجلة	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	مجلة	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	مختبر	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1602	مجلة	Trissel LA, Zhang Y, Cohen MR. The stablity of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm 2001 ; 36: 740-745.
1606	مجلة	Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625	مجلة	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	مجلة	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	مجلة	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	مجلة	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	مجلة	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2094	مجلة	Trittler R. Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS. EJHP Science 2006 ; 12, 1: 10-12.
2247	مجلة	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3119	الملصق	Henriet Th, El Kateb N, Jourdan N, Faure P, Bellenger P. Stabilité de la vincristine sans conservateurs. Congrès HOPIPHARM 2010
3214	مجلة	Trittler R, Sewell G. Stability of vincristine (TEVA) in original vials after re-use in dilute infusions in polyolefin bags and in polypropylene syringes. EJOP 2011 ; 5,1: 10-14.
3578	مختبر	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3644	مختبر	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
4102	مجلة	Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care. J Oncol Pharm Practice 2018 ;25,4:831-840.

Mentions Légales